Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis

In conclusion, infliximab causes significant improvement in FVC in refractory 18F-FDG PET positive sarcoidosis. Especially in pulmonary disease, high 18F-FDG PET SUVmax values at treatment initiation predict clinically relevant lung function improvement. These results suggest that inclusion of 18F-FDG PET is useful in therapeutic decision-making in complex sarcoidosis.

Source: European Respiratory Journal - June 30, 2015 Category: Respiratory Medicine Authors: Vorselaars, A. D. M., Crommelin, H. A., Deneer, V. H. M., Meek, B., Claessen, A. M. E., Keijsers, R. G. M., van Moorsel, C. H. M., Grutters, J. C. Tags: Interstitial and orphan lung disease Original Articles: Sarcoidosis Source Type: research